DR5 receptor mediates anoikis in human colorectal carcinoma cell lines

被引:40
|
作者
Laguinge, Luciana M. [1 ]
Samara, Raed N. [1 ]
Wang, Wenge [3 ]
El-Deiry, Wafik S. [3 ]
Corner, Georgia [4 ]
Augenlicht, Leonard [4 ]
Mishra, Lopa [2 ]
Jessup, J. Miburn [1 ]
机构
[1] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA
[2] Georgetown Univ, Med Ctr, Dept Surg, Washington, DC 20007 USA
[3] Univ Penn, Sch Med, Abramson Canc Ctr, Dept Med, Philadelphia, PA 19104 USA
[4] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA
关键词
D O I
10.1158/0008-5472.CAN-06-1806
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As human colorectal cancer (CRC) cells metastasize to distant sites, they are susceptible to detachment-induced cell death or anoikis - a form of apoptosis that occurs when anchorage-dependent CRC cells go into suspension. Our goal was to identify whether tumor necrosis factor receptor apoptosis-inducing ligand (TRAIL) receptors mediate anoikis in human CRC cells. First, we assessed whether caspases of the extrinsic (caspase-8) or intrinsic (caspase-9) death pathways were involved. Caspase-8 was cleaved during exposure to suspension culture in four CRC lines, and cell death was inhibited by caspase-3 and caspase-8 inhibitors but not by a caspase-9 inhibitor. Gene transcripts in macrophage inflammatory protein-101 (MIP-110), a weakly metastatic human CRC, were increased at least 2-fold for TRAIL-R2 (DR5) and TRAIL after 24 h of suspension culture compared with cells in monolayer culture. The increased expression of DR5 was confirmed at the protein level at 24 h, and exposure of MIP-101 cells to an antagonistic antibody to DR5 decreased caspase-8 activation. The antagonistic antibody to DR5 inhibited anoikis in four human CRC lines. Treatment with an antagonistic DR4 antibody or a neutralizing antibody to TRAIL ligand did not reduce anoikis consistently. Knockdown of DR5 or TRAIL also inhibited anoikis, whereas exogenous TRAIL or FasL did not consistently increase anoikis. In summary, DR5 receptor mediates death signals for anoikis in human CRC cells through the extrinsic apoptotic pathway.
引用
收藏
页码:909 / 917
页数:9
相关论文
共 50 条
  • [1] TRAIL DR5 receptor mediates anoikis in human colorectal carcinoma cell lines through the extrinsic apoptotic pathway
    Laguinge, Luciana M.
    Samara, Raed
    Jessup, John M.
    CANCER RESEARCH, 2006, 66 (08)
  • [2] Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with Trail-R2 (DR5) signaling
    Samara, Raed N.
    Laguinge, Luciana M.
    Jessup, J. Milburn
    CANCER RESEARCH, 2007, 67 (10) : 4774 - 4782
  • [3] Differential expression and function of DR5 and Fas in human T cell lines
    Li, L
    Ichikawa, K
    Liu, W
    Wang, Z
    Zhou, T
    FASEB JOURNAL, 2000, 14 (06): : A1224 - A1224
  • [4] A novel human-mouse chimeric death receptor (DR5) molecule mediates TRA-8 induced apoptosis in mouse cell lines
    Li, Jun
    Yang, Ping-Ar
    Hsu, Hui-Chen
    Mountz, John D.
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [5] Both TRAIL receptor DR5 isoforms are required for the induction of cell death in human colon carcinoma
    Jani, Tanvi S.
    DeVecchio, Jennifer
    Peters, Kristi
    Houghton, Janet
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [6] Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma
    Jeng, YM
    Hsu, HC
    CANCER LETTERS, 2002, 181 (02) : 205 - 208
  • [7] Downregulation of external death receptor genes FAS and DR5 in colorectal cancer samples positive for human papillomavirus infection
    Karbasi, Ashraf
    Borhani, Nasim
    Daliri, Karim
    Kazemi, Bahram
    Manoochehri, Mehdi
    PATHOLOGY RESEARCH AND PRACTICE, 2015, 211 (06) : 444 - 448
  • [8] Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas
    Arai, T
    Akiyama, Y
    Okabe, S
    Saito, K
    Iwai, T
    Yuasa, Y
    CANCER LETTERS, 1998, 133 (02) : 197 - 204
  • [9] First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer
    Wang, Shujing
    Zhu, Hua
    Li, Yingjie
    Ding, Jin
    Wang, Feng
    Ding, Lixin
    Wang, Xinyu
    Zhao, Jun
    Zhang, Yan
    Yao, Yunfeng
    Zhou, Tong
    Li, Nan
    Wu, Aiwen
    Yang, Zhi
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [10] Small-molecule activation of the TRAIL receptor DR5 in human cancer cells
    Wang G.
    Wang X.
    Yu H.
    Wei S.
    Williams N.
    Holmes D.L.
    Halfmann R.
    Naidoo J.
    Wang L.
    Li L.
    Chen S.
    Harran P.
    Lei X.
    Wang X.
    Nature Chemical Biology, 2013, 9 (2) : 84 - 89